Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term extension study of faricimab in neovascular age-related macular degeneration
MOH_2021-05-25_009997Phase 3Completed
- Sponsor
- Roche Pharmaceuticals Israel
- Start
- May 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of faricimab in exudative macular degeneration, sponsored by Roche Pharmaceuticals Israel. Primary endpoints: Incidence and severity of ocular adverse events and Incidence and severity of non-ocular adverse events. Started May 2021; status: completed.
02
Drugs
faricimab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on MOH_2021-05-25_009997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-05-25_009997.